Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 -2.10%90 Net Margin % is 16.10% as of Mar. 2026, which is 8% below its 10-year median of 17.57. GuruFocus rates BOM:543904 with a GF Score™ of 90/100 and a GF Value™ of ₹2,934.91 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Mankind Pharma ranks better than 74.4% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Mankind Pharma's Net Income for the
three
months ended in Mar. 2026 was ₹5,544 Mil. Mankind Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹34,429 Mil. Therefore, Mankind Pharma's net margin for the quarter that ended in Mar. 2026 was 16.10%.
The historical rank and industry rank for Mankind Pharma's Net Margin % or its related term are showing as below:
BOM:543904'
s Net Margin % Range Over the Past 10 Years
Min: 13.4 Med: 17.57 Max: 20.36
Current: 13.4
BOM:543904's Net Margin % is ranked better than 74.4% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs BOM:543904: 13.40
Mankind Pharma (BOM:543904) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Mankind Pharma Net Margin % Related Terms
Mankind Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mankind Pharma (BOM:543904) has a Net Margin % of 16.10% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Mankind Pharma and its competitors. This is near median its historical median of 17.57. Over the past decade, Mankind Pharma's Net Margin % has ranged from 13.40 to 20.36. According to the industry distribution chart, Mankind Pharma ranks #246 out of 961 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is Mankind Pharma's Net Margin % too high?
Mankind Pharma's current Net Margin % of 16.10% is near median its 10-year median of 17.57. Over the past 10 years, this metric has ranged from a low of 13.40 to a high of 20.36. The Drug Manufacturers industry median Net Margin % is 5.58. Mankind Pharma's value of 16.10% is 188.5% above this industry median. Based on the distribution chart, Mankind Pharma ranks #246 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #246 out of 961 companies for Net Margin %. This puts Mankind Pharma in the upper half of its industry. The industry median Net Margin % is 5.58. Mankind Pharma's value of 16.10% is 188.5% above this benchmark. Historically, Mankind Pharma's own Net Margin % has ranged from 13.40 to 20.36 over the past decade. While the company's 10-year median is 17.57 vs. the industry median of 5.58, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current Net Margin % of 16.10% is 188.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current Net Margin % is 16.10%, which is near median its own 10-year median of 17.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,934.91, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current Net Margin % is 16.10%, which is near median its 10-year median of 17.57 and 188.5% above the Drug Manufacturers industry median of 5.58. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Net Margin % is 16.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,934.91.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
Net Margin %: 16.10% (near median its 10-year median of 17.57)
GF Value™: ₹2,934.91 vs. price of ₹2,491.45 (15.1% below fair value)
Industry Position: 188.5% above the Drug Manufacturers median (#246 of 961)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score
Get the complete analysis for BOM:543904
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
